Lotus Eye Hospital & Institute Ltd

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with an up-to-date view of its performance and prospects.

Lotus Eye Hospital & Institute Ltd (NSE: 959118) surged to its upper circuit limit on 4 Feb 2026, closing at ₹123.72, marking a maximum daily gain of 5.0%. This sharp rally was driven by robust buying interest, signalling a potential trend reversal after four consecutive days of decline. The stock outperformed its hospital sector peers and the broader market, reflecting renewed investor confidence in this micro-cap healthcare player.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 2 Feb 2026, closing at ₹122.09, down 5.0% on the day. The stock faced intense selling pressure, with volumes concentrated near the day’s low, reflecting panic selling and unfilled supply in the micro-cap hospital sector stock.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 1 Feb 2026, reflecting intense selling pressure and heightened volatility. The stock closed at ₹128.51, down 5.0% on the day, marking a maximum daily loss as panic selling gripped investors amid unfilled supply and cautious market sentiment.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 30 Jan 2026, succumbing to intense selling pressure that saw the stock close at ₹134.32, down 4.99% on the day. This sharp decline followed a seven-day winning streak, signalling a sudden shift in investor sentiment and triggering panic selling in the micro-cap hospital sector stock.

Lotus Eye Hospital & Institute Ltd has reached a significant milestone by hitting a new 52-week and all-time high of Rs.147.6 today, marking a remarkable rally in the hospital sector amid a mixed market environment.

Lotus Eye Hospital & Institute Ltd has reached a significant milestone, hitting an all-time high of Rs.147.6 on 30 Jan 2026, marking a remarkable phase in the company’s market performance and reflecting sustained investor confidence in the hospital sector.

Lotus Eye Hospital & Institute Ltd (stock code 959118) surged to its upper circuit limit on 29 Jan 2026, closing at a new 52-week and all-time high of ₹141.38. The hospital sector stock demonstrated strong buying interest, outperforming its sector and broader market indices, signalling renewed investor confidence and robust demand despite its micro-cap status.

Lotus Eye Hospital & Institute Ltd has surged to a fresh 52-week and all-time high of Rs.141.1, marking a significant milestone in its stock performance. This new peak reflects sustained momentum, with the stock outperforming its sector and demonstrating robust gains over the past week.

Lotus Eye Hospital & Institute Ltd has reached a significant milestone by hitting a new all-time high of Rs.141.1, marking a remarkable phase in its market journey. The stock’s strong performance over recent periods underscores the company’s sustained growth within the hospital sector.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 January 2026, providing investors with an up-to-date perspective on its performance and outlook.

Shares of Lotus Eye Hospital & Institute Ltd surged to hit the upper circuit limit on 28 Jan 2026, propelled by strong buying interest and sustained positive momentum. The stock closed at ₹134.00, marking a 4.47% gain on the day and outperforming its sector and benchmark indices significantly.

Lotus Eye Hospital & Institute Ltd (NSE: 959118) surged to its upper circuit limit on 27 Jan 2026, closing at ₹128.27, marking a 4.99% gain on the day. This rally was driven by robust buying interest, with the stock outperforming its hospital sector peers and the broader market indices, signalling renewed investor confidence in this micro-cap healthcare player.

Shares of Lotus Eye Hospital & Institute Ltd surged to hit the upper circuit limit on 23 Jan 2026, propelled by robust buying interest and sustained positive momentum. The stock closed at ₹122.18, marking a maximum daily gain of 4.99%, significantly outperforming its hospital sector peers and the broader market indices.

Lotus Eye Hospital & Institute Ltd witnessed robust buying interest on 22 Jan 2026, hitting its upper circuit limit and registering a maximum daily gain of 5%. The stock’s strong performance comes amid rising investor participation and a notable surge in delivery volumes, signalling renewed confidence in this hospital sector micro-cap.

Lotus Eye Hospital & Institute Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 30 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of its performance and prospects.

Shares of Lotus Eye Hospital & Institute Ltd plunged to their lower circuit limit on 29 Dec 2025, reflecting intense selling pressure and panic among investors. The stock closed at ₹121.76, marking a maximum daily loss of 4.99%, underperforming its sector and broader market indices amid thin volumes and unfilled supply.